CellAegis Devices, Inc. receives Investigational Testing Approval from Health Canada

February 27, 2013: CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval (ITA) from Health Canada that allows the initiation of clinical testing in Canada of the Company’s autoRICTM Device for Chronic Remote Ischemic Conditioning (CRIC). In a Canadian Institutes of Health Research (CIHR-sponsored Phase II, randomized, double-blind, placebo-controlled, multi-center clinical study, CRIC will be evaluated for its ability to reduce adverse left ventricular remodeling following primary percutaneous coronary intervention (PCI) for St-segment elevation myocardial infarction (STEMI).

Press Release